Kheiron Medical Technologies

Transforming cancer diagnostics through the power of deep learning.

Giving patients a better fighting chance against cancer

At Kheiron, we create Artificial Intelligence (AI) solutions that really make a difference. By helping radiologists detect cancer earlier, our next-generation technology can increase chances of survival and pave the way for less invasive treatments*. All while helping radiology departments run more efficiently and manage patient care more effectively.

*Kheiron clinical study

Read on to explore our story, beliefs and solutions. And join the AI revolution.

Partners

We’re doing important work with a range of pioneering organisations around the globe.

About Kheiron Medical Technologies

Learn about the people who inspire us and the challenges that drive us.

The Kheiron constellation

Our first solution: Revolutionising mammography

Mia®, whose name comes from Mammography Intelligent Assessment, is our breakthrough AI platform for breast screening. Bringing together a suite of solutions, Mia empowers radiologists and screening services to deliver confident, accurate, timely results. Ultimately, Mia supports radiologists in making the most important breast screening decision — should this woman be called back for further testing or not?

Why breast screening?

With our first solution, we chose to focus specifically on how AI could improve breast screening programmes. Why? Because early detection is directly linked to better outcomes for women. 

The American Cancer Society (ACS) found that the five-year survival rate for women receiving an early-stage (localised) breast cancer diagnosis is 99%*. When diagnosis occurs at the regional stage, survivorship falls to 86% – and then again to 28% at the distant stage**. 

But breast screening is only the beginning. We’re currently looking ahead at how AI can revolutionise diagnostics for other types of cancer. Watch this space.

*Living with breast cancer: Statistics on survival rates by stage

**Survival Rates for Breast Cancer

Tackling the radiology workforce crisis in the UK’s National Health Service

Across the globe, radiology departments are overworked and understaffed. The good news is, AI is already helping to solve this crisis for parts of the NHS.

Learn how, in this lively, must-watch webinar.

Latest articles

Latest articles

PR

11th May 2022

Kheiron Forms US Breast Medical Advisory Board; Appoints Three Leaders With Deep Track Record Advocating For Women’s Health

Dr. Wendy DeMartini, Dr. Elizabeth Morris, and Dr. Amy Patel are trailblazers at the forefront of introducing innovative breast imaging technologies into clinical practice (London …

Read more
Latest articles

PR

4th May 2022

InHealth signs up to AI Award with Kheiron

InHealth, who provide services for North and East Devon NHS Breast Screening, has entered into the research agreement to work with Kheiron Medical Technologies as part of the AI in…

Read more
Latest articles

PR

9th March 2022

Kheiron included in Fast Company’s Most Innovative Companies 2022 list

This AI cancer diagnostics company joins the ranks of Canva, Microsoft, SpaceX, and other winning companies that are changing lives for the better (London –  March 9, 20…

Read more

About Kheiron

Events

Upcoming events and conferences around the world

Resources

Learn

Case studies, blogs, and Kheiron news and opinions.

About Kheiron

Leading the charge:
Our story

When co-founders Peter Kecskemethy and Tobias Rijken met in 2016, they started with a question: How could AI help to detect cancer sooner, and improve the lives of patients and radiologists around the world? Discover where this spark of inspiration led them.

Partners

Working together towards a better future

We have big ambitions, but we can’t achieve them alone. Learn about our partners, our clinical studies and how you can get involved.

Contact us

Want to give your patients a better fighting chance against cancer? We’re eager to understand your perspective and explore how we can help you.

Contact us using the details below.